Business
Licenses CSD500 to RFSU AB in the Nordic Region
Licenses CSD500 to RFSU AB in the Nordic Region.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 9135V Futura Medical PLC 19 December 2013 \n\n\n\n\n\nFor immediate release \n\n\n19 December 2013\n\n\n\n\n \n \nFutura Medical PLC\n(\"Futura\" or the \"Company\")\n \nLicenses CSD500 to RFSU AB in the Nordic Region\n \nFutura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that it has signed an exclusive licensing agreement with Sweden's RFSU AB for the marketing and distribution of CSD500, Futura's novel condom, in Sweden, Norway, Finland and Denmark.\n \nThis agreement is in line with Futura's strategy of licensing CSD500 to condom distributors that hold leading positions in their regions. RFSU AB is the market leader in the four Nordic countries included in this agreement. \n \nRegulatory authorisation in all of the countries included in this agreement is provided by CSD500's CE mark, which was awarded earlier this year.\n \nUnder the terms of the agreement, RFSU AB will hold the rights to manufacture, market and distribute CSD500 in Sweden, Norway, Finland and Denmark.\n \nThe financial details of the agreement are not being disclosed although Futura will receive an upfront payment and royalties on all product sales along with certain minimum performance guarantees.\n \nKatarina Knutz, Managing Director of RFSU AB, commented: \"Our objective is to promote innovation in condom design to provide choice to our customers. CSD500 is a highly attractive addition to our product portfolio as the uniqueness of its design brings the potential to encourage the wider use of condoms.\" \n \nJames Barder, Futura's Chief Executive, commented: \"We are delighted to sign this exclusive agreement with RFSU AB for the marketing of CSD500 in Sweden, Norway, Finland and Denmark. RFSU AB has leading market positions in these four countries, all of which use the CE mark for regulatory authorisation. We look forward to RFSU AB's launch of CSD500 in the Nordic Region during 2014.\"\n \n \nFor further information: \n \n\n\n\n\nFutura Medical plc\n\n\n+ 44 (0) 1483 685 670\n\n\n\n\nJames Barder, Chief Executive\n\n\n\n\n\n\n\nMail to: [email protected]\n\n\nwww.futuramedical.com\n\n\n\n\n\n\n\n\n\n\n\n\nCenkos Securities plc\n\n\n+ 44 (0) 20 7397 8927\n\n\n\n\nBobbie Hilliam\n\n\n\n\n\...